Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
$6.84
$0.35(10.45%)
At close: 4:00 PM EST
$6.84
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.50 - $8.60
Previous CloseN/A
Volume116.73K
Average Volume (3M)231.42K
Market Cap
$641.59M
Enterprise Value$639.34M
Total Cash (Recent Filing)$76.90M
Total Debt (Recent Filing)$13.73M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 25, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding88,009,735
10 Day Avg. Volume197,599
30 Day Avg. Volume231,424
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.39
Forecast
1Y Price Target
$8.67Price Target Upside26.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.27M
Bulls Say, Bears Say
Bulls Say
Clinical Development MomentumMultiple ongoing U.S. clinical trials in skin cancer, pancreatic cancer and glioblastoma with upcoming data releases could materially strengthen the therapy's value proposition and attract licensing or acquisition interest if results are favorable.
Manufacturing And Commercialization StrategyPlanned onsite manufacturing in New Hampshire combined with a strategy to partner for commercialization in Japan can expand production capacity, conserve resources and accelerate market access versus building an in-house salesforce.
Regulatory ApprovalJapan regulatory approval for Alpha DaRT to treat unresectable or locally recurrent head and neck cancer validates the therapeutic platform and lowers development risk for expansion into additional tumor types and markets.
Bears Say
Commercialization Timeline And Payer RiskCommercialization depends on positive trial outcomes, regulatory approvals and securing payer coverage, creating uncertainty around when the company will start generating meaningful revenue.
Financial Performance And ValuationReported net losses exceeded analyst expectations and an analyst downgrade citing a stretched valuation indicates further upside may require the company to begin generating sustainable revenue.
Management And Partnership UncertaintyThe chief commercial officer's departure and early-stage partnership negotiations raise questions about near-term commercial execution and the timing and scale of potential market expansion.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.50 and its highest was $8.60 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $641.59M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is May 25, 2026 which is in 42 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Mar 09, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.019.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.12.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 88,009,735 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went up 1.937%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.67 (26.75% Upside)
$8.67 (26.75% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
191.60%
12-Months-Change
Fundamentals
Return on Equity
-57.29%
Trailing 12-Months
Asset Growth
23.64%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$8.67
▲(26.75% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
99.41% Public Companies and
Individual Investors